3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule

NCT02034773 | Completed Phase 1

• 1 other identifier: CC-220-CP-002
• Study Type: interventional
• Target: 64
• Locations: 1 country
• Sites: 1

Brief Summary

To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of CC-220 in healthy subjects and to evaluate the relative bioavailability of a formulated CC-220 capsule

Conditions

Healthy Volunteers

Keywords

Safety, Pharmacokinetics, Pharmacodynamics, Healthy Subjects

Outcome Measures

Primary Outcomes (1)

• Adverse Events

  Number of participants with adverse events

  Up to 7 months overall

Secondary Outcomes (11)

• Concentrations of CC-220 and its R-enantiomer in plasma

  Up to 30 days per cohort

• Pharmacodynamic Assessmens

  Up to 42 days per cohort

• Pharmacokinetics - Cmax

  Up to 30 days

• Pharmacokinetics - tmax

  Up to 30 days

• Pharmacokinetics - AUCinf

  Up to 30 days

Study Arms (8)

CC-220 0.3mg x 14 days

EXPERIMENTAL

Drug: CC-220

CC-220 1mg x 28 days

EXPERIMENTAL

Drug: CC-220

CC-220 0.3mg x 28 days

EXPERIMENTAL

Drug: CC-220

CC-220 1mg x a total of 14 days

EXPERIMENTAL

Drug: CC-220

Placebo

EXPERIMENTAL

Drug: Placebo

CC-220 0.3mg (once every 3 days for 14 days)

EXPERIMENTAL

Drug: CC-220

CC-220 1mg (once every 7 days for 28 days)

EXPERIMENTAL

Drug: CC-220

CC-220 1mg (formulated and reference capsules)

EXPERIMENTAL

Drug: CC-220

Interventions

CC-220 DRUG

CC-220 0.3mg will be administered once daily for 14 days

CC-220 0.3mg x 14 days

Placebo DRUG

Placebo will be administered once daily for up to 28 days

Placebo

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• \. Must understand and voluntarily sign a written informed consent document prior to any study-related procedures being performed.
• \. Must be able to communicate with the investigator, understand and comply with the requirements of the study, and agree to adhere to restrictions and examination schedules.
• \. Healthy male or female of any race between 18 to 55 years of age (inclusive) at the time of signing the informed consent document, and in good health as determined by a physical examination.
• \. For males: Agree to use barrier contraception not made of natural (animal) membrane \[e.g., latex or polyurethane condoms are acceptable\]) when engaging in sexual activity with a female of childbearing potential while on study medication, and for at least 28 days after the last dose of study medication.
• For females: Female subjects must have been surgically sterilized (hysterectomy or bilateral oophorectomy; proper documentation required) at least 6 months before screening, or be postmenopausal (defined as 24 months without menses before screening, with an estradiol level of \< 30 pg/mL and follicle-stimulating hormone level of \> 40 IU/L at screening).
• \. Must have a body mass index between 18 and 33 kg/m2 (inclusive). 6. Clinical laboratory tests must be within normal limits or acceptable to the investigator. Platelet count, absolute neutrophil count and absolute lymphocyte count must be above the lower limit of normal at the screening visit.
• \. Subject must be afebrile, with supine systolic blood pressure: 90 to 140 mmHg, supine diastolic blood pressure: 50 to 90 mmHg, and pulse rate: 40 to 110 bpm.
• \. Must have a normal or clinically-acceptable 12-lead electrocardiogram at screening. Male subjects must have a QTcF value ≤ 430 msec. Female subjects must have a QTcF value ≤ 450 msec.
• \. Antitetanus immunoglobulin G titer ≥ 0.1 IU/mL to ensure prior exposure of tetanus toxoid. Note: This criterion only applies to those subjects who will be dosed once daily for 28 days.

You may not qualify if:

• \. History of any clinically significant and relevant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematological, allergic disease, drug allergies, or other major disorders.
• \. Any condition which places the subject at unacceptable risk if he or she were to participate in the study, or confounds the ability to interpret data from the study.
• \. Used any prescribed systemic or topical medication (including but not limited to analgesics, anesthetics, etc) within 30 days of the first dose administration, unless sponsor agreement is obtained.
• \. Used any non-prescribed systemic or topical medication (including vitamin/mineral supplements, and herbal medicines) within 14 days of the first dose administration, unless sponsor agreement is obtained.
• \. Used CYP3A inducers and inhibitors (including St. John's Wort) within 30 days of the first dose administration.
• \. Has any surgical or medical conditions possibly affecting drug absorption, distribution, metabolism and excretion, e.g., bariatric procedure. Appendectomy and cholecystectomy are acceptable.
• \. Donated blood or plasma within 8 weeks before the first dose administration to a blood bank or blood donation center.
• \. History of drug abuse (as defined by the current version of the Diagnostic and Statistical Manual) within 2 years before dosing, or positive drug screening test reflecting consumption of illicit drugs.
• \. History of alcohol abuse (as defined by the current version of the Diagnostic and Statistical Manual) within 2 years before dosing, or positive alcohol screen.
• \. Known to have serum hepatitis or known to be a carrier of hepatitis B surface antigen or hepatitis c antibody, or have a positive result to the test for human immunodeficiency virus antibodies at screening.
• \. Exposed to an investigational drug (new chemical entity) within 30 days preceding the first dose administration, or 5 half-lives of that investigational drug, if known (whichever is longer).
• \. Smoke more than 10 cigarettes per day, or the equivalent in other tobacco products (self reported).
• \. Vaccination within 30 days of dosing or plans to receive vaccination within 30 days after dosing. Systemic infection within 30 days of dosing.
• \. Tetanus vaccination within 5 years prior to the first dose administration. Note: This criterion only applies to those subjects who will be dosed once daily for 28 days.
• \. Pneumococcal vaccination within 3 years prior to the first dose administration. Note: This criterion only applies to those subjects who will be dosed once daily for 28 days.

Sponsors & Collaborators

• Celgene Corporation: lead

Study Sites (1)

Covance Clinical Research Unit

Madison, Wisconsin, 53704, United States

Location

MeSH Terms

Interventions

iberdomide

Study Officials

• Daniel Weiss, MD

  Celgene

  STUDY DIRECTOR

• Debra Mandarino, MD

  Covance

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 10, 2014
• First Posted: January 13, 2014
• Study Start: May 1, 2013
• Primary Completion: December 1, 2013
• Study Completion: December 1, 2013
• Last Updated: January 13, 2014

Record last verified: 2014-01

Locations

US (1)